首页 > 最新文献

Journal of Ophthalmic Inflammation and Infection最新文献

英文 中文
Stenotrophomonas maltophilia endophthalmitis following keratoplasty. 角膜移植术后嗜麦芽窄食单胞菌性眼内炎。
IF 2.9 Q2 Medicine Pub Date : 2023-10-13 DOI: 10.1186/s12348-023-00368-9
Bilge Tarım, Mücella Arıkan Yorgun, Birsen Özdem, Emine Kalkan Akçay

Endophthalmitis is among the most sight-threatening infections in ophthalmology practice. Many microorganisms causing endophthalmitis have been reported. Stenotrophomonas maltophilia is among the rare causes of endophthalmitis and has been reported after cataract surgery, intravitreal injections and ocular trauma. We report a case of S. maltophilia endophthalmitis after keratoplasty, which is a rare entity, in a 63-year-old female patient.

眼内炎是眼科实践中最具视力威胁的感染之一。已经报道了许多引起眼内炎的微生物。嗜麦芽窄食单胞菌是眼内炎的罕见原因之一,在白内障手术、玻璃体内注射和眼部创伤后均有报道。我们报告一例63岁女性患者在角膜移植术后发生嗜麦芽糖链球菌眼内炎,这是一种罕见的疾病。
{"title":"Stenotrophomonas maltophilia endophthalmitis following keratoplasty.","authors":"Bilge Tarım, Mücella Arıkan Yorgun, Birsen Özdem, Emine Kalkan Akçay","doi":"10.1186/s12348-023-00368-9","DOIUrl":"10.1186/s12348-023-00368-9","url":null,"abstract":"<p><p>Endophthalmitis is among the most sight-threatening infections in ophthalmology practice. Many microorganisms causing endophthalmitis have been reported. Stenotrophomonas maltophilia is among the rare causes of endophthalmitis and has been reported after cataract surgery, intravitreal injections and ocular trauma. We report a case of S. maltophilia endophthalmitis after keratoplasty, which is a rare entity, in a 63-year-old female patient.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"13 1","pages":"46"},"PeriodicalIF":2.9,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41203534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Branch retinal vein occlusion in a case of recalcitrant diffuse anterior scleritis treated with tofacitinib. 托法替尼治疗顽固性弥漫性前巩膜炎的视网膜分支静脉阻塞。
IF 2.9 Q2 Medicine Pub Date : 2023-09-27 DOI: 10.1186/s12348-023-00359-w
Anitha Manoharan, Harshita Atmakur, Parthopratim Dutta Majumder, Jyotirmay Biswas

A 47-year-old woman with hypertension and rheumatoid arthritis presented with non-necrotizing scleritis in both eyes. Despite a course of oral corticosteroids, she continued to experience persistent symptoms. A rheumatologist was consulted and initiated treatment with tofacitinib, a JAK/STAT inhibitor. Treatment with tofacitinib and oral corticosteroids resulted in an improvement in the scleritis in both eyes. However, a fundus examination of her left eye revealed a superior-temporal branch retinal vein occlusion. Given the growing concern regarding the increased risk of thromboembolic events with tofacitinib therapy, it is essential to consider the risk of retinal vascular occlusions when starting tofacitinib therapy, particularly in patients with underlying systemic comorbidities.

一名47岁女性,患有高血压和类风湿性关节炎,双眼出现非坏死性巩膜炎。尽管进行了一个疗程的口服皮质类固醇治疗,但她仍持续出现症状。咨询了风湿病学家,并开始使用JAK/STAT抑制剂托法替尼进行治疗。托法替尼和口服皮质类固醇治疗使双眼巩膜炎得到改善。然而,对她的左眼进行的眼底检查显示,她的颞上支视网膜静脉阻塞。鉴于人们越来越担心托法替尼治疗会增加血栓栓塞事件的风险,在开始托法替尼治疗时,尤其是在有潜在全身合并症的患者中,必须考虑视网膜血管闭塞的风险。
{"title":"Branch retinal vein occlusion in a case of recalcitrant diffuse anterior scleritis treated with tofacitinib.","authors":"Anitha Manoharan, Harshita Atmakur, Parthopratim Dutta Majumder, Jyotirmay Biswas","doi":"10.1186/s12348-023-00359-w","DOIUrl":"10.1186/s12348-023-00359-w","url":null,"abstract":"<p><p>A 47-year-old woman with hypertension and rheumatoid arthritis presented with non-necrotizing scleritis in both eyes. Despite a course of oral corticosteroids, she continued to experience persistent symptoms. A rheumatologist was consulted and initiated treatment with tofacitinib, a JAK/STAT inhibitor. Treatment with tofacitinib and oral corticosteroids resulted in an improvement in the scleritis in both eyes. However, a fundus examination of her left eye revealed a superior-temporal branch retinal vein occlusion. Given the growing concern regarding the increased risk of thromboembolic events with tofacitinib therapy, it is essential to consider the risk of retinal vascular occlusions when starting tofacitinib therapy, particularly in patients with underlying systemic comorbidities.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"13 1","pages":"45"},"PeriodicalIF":2.9,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41148061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ocular manifestations following COVID-19 vaccination. 新冠肺炎疫苗接种后的眼部表现。
IF 2.9 Q2 Medicine Pub Date : 2023-09-23 DOI: 10.1186/s12348-023-00358-x
Padmamalini Mahendradas, Sai Bhakti Mishra, Rohini Sangoram, Sanjay Srinivasan, Ankush Kawali, Aditya Patil, Rohit Shetty

Background: Immunologic and inflammatory adverse effects following vaccination against COVID-19 are being reported. While some reactions may develop denovo others concern its immunogenic effect in patients with pre-existing inflammatory conditions.

Methods: Retrospective consecutive patients diagnosed with ocular inflammatory manifestations within 8 weeks of receiving COVID-19 vaccination who presented to a tertiary eye care centre in South India.

Results: Ninety-eight eyes of 67 patients presenting with ocular inflammatory manifestations within 8 weeks following COVID-19 vaccination were studied. The mean age was 43 years (+/- 14.82; range 19-80 years). The most common presentations were anterior uveitis (n = 31, 31.7%), followed by panuveitis (n = 24, 24.5%). The mean time to onset of symptoms was 25 days (+/- 15.48; range 2-55 days) following a dose of vaccine. Among all patients, 39 (58.2%) had a previous history of ocular inflammation. Mean presenting visual acuity was 0.4 (0-4) logMAR units and mean final visual acuity was 0.2 (0-4) logMAR units. The causes for reduced vision included of cystoid macular edema (n=2, 2%), chorioretinal atrophy (n=2.2%), optic atrophy (n=1.1%), retinal vascular occlusion (n=1.1%) and acute retinal necrosis (n=1.1%).

Conclusion: Infective and immunogenic adverse events should be watched out for after COVID-19 vaccination. It is difficult to establish causality for such manifestations, nevertheless, most of them were mild and had good final visual outcomes.

背景:报道了接种新冠肺炎疫苗后的免疫和炎症不良反应。虽然一些反应可能会发展为denovo,但其他反应则涉及其对已有炎症条件的患者的免疫原性影响。方法:回顾性研究在接受新冠肺炎疫苗接种后8周内被诊断为眼部炎症表现的连续患者,这些患者在南印度的三级眼科护理中心就诊。平均年龄43岁(+/-14.82;范围19-80岁)。最常见的表现是前葡萄膜炎(n = 31.7%),其次为全葡萄膜炎(n = 24,24.5%)。接种一剂疫苗后症状出现的平均时间为25天(+/-15.48;范围为2-55天)。在所有患者中,39人(58.2%)有眼部炎症病史。平均呈现视力为0.4(0-4)logMAR单位,平均最终视力为0.2(0-4(logMAR)单位。视力下降的原因包括囊样黄斑水肿(n=2,2%)、脉络膜视网膜萎缩(n=2.2%)、视神经萎缩(n=1.1%)、视网膜血管阻塞(n=1.1%,1.1%)和急性视网膜坏死(n=1.1%)。结论:接种新冠肺炎疫苗后应注意感染性和免疫原性不良事件。很难确定这种表现的因果关系,然而,大多数表现都很轻微,最终视觉效果良好。
{"title":"Ocular manifestations following COVID-19 vaccination.","authors":"Padmamalini Mahendradas, Sai Bhakti Mishra, Rohini Sangoram, Sanjay Srinivasan, Ankush Kawali, Aditya Patil, Rohit Shetty","doi":"10.1186/s12348-023-00358-x","DOIUrl":"10.1186/s12348-023-00358-x","url":null,"abstract":"<p><strong>Background: </strong>Immunologic and inflammatory adverse effects following vaccination against COVID-19 are being reported. While some reactions may develop denovo others concern its immunogenic effect in patients with pre-existing inflammatory conditions.</p><p><strong>Methods: </strong>Retrospective consecutive patients diagnosed with ocular inflammatory manifestations within 8 weeks of receiving COVID-19 vaccination who presented to a tertiary eye care centre in South India.</p><p><strong>Results: </strong>Ninety-eight eyes of 67 patients presenting with ocular inflammatory manifestations within 8 weeks following COVID-19 vaccination were studied. The mean age was 43 years (+/- 14.82; range 19-80 years). The most common presentations were anterior uveitis (n = 31, 31.7%), followed by panuveitis (n = 24, 24.5%). The mean time to onset of symptoms was 25 days (+/- 15.48; range 2-55 days) following a dose of vaccine. Among all patients, 39 (58.2%) had a previous history of ocular inflammation. Mean presenting visual acuity was 0.4 (0-4) logMAR units and mean final visual acuity was 0.2 (0-4) logMAR units. The causes for reduced vision included of cystoid macular edema (n=2, 2%), chorioretinal atrophy (n=2.2%), optic atrophy (n=1.1%), retinal vascular occlusion (n=1.1%) and acute retinal necrosis (n=1.1%).</p><p><strong>Conclusion: </strong>Infective and immunogenic adverse events should be watched out for after COVID-19 vaccination. It is difficult to establish causality for such manifestations, nevertheless, most of them were mild and had good final visual outcomes.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"13 1","pages":"44"},"PeriodicalIF":2.9,"publicationDate":"2023-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41179169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Idiopathic sclerosing dacryoadenitis. 特发性硬化性泪腺炎。
IF 2.9 Q2 Medicine Pub Date : 2023-09-19 DOI: 10.1186/s12348-023-00365-y
Samantha D Butterfield, Rona Z Silkiss

Dacryoadenitis is an inflammation of the lacrimal gland. This condition has an extensive differential diagnosis, requiring a thorough workup to identify the underlying etiology. If no etiology is identified, the condition is termed idiopathic dacryoadenitis. The purpose of this report is to present a case of idiopathic sclerosing dacryoadenitis and review the diagnostic process.We present a case of sclerosing dacryoadenitis non responsive to systemic antibiotics and steroids, improving after surgical debulking/biopsy. Systemic inflammatory and infectious labs were negative. Tissue was negative for SARS-CoV-2 antigen. Histopathologic review of the surgical specimen revealed nonspecific, sclerosing dacryoadenitis, ultimately supporting the diagnosis of idiopathic nonspecific fibrosing dacryoadenitis.This case reviews the presentation, evaluation, and management of a common orbital pathologic condition, with updated recommendations based on the most current literature.

泪腺腺炎是一种泪腺炎症。这种情况有广泛的鉴别诊断,需要彻底检查以确定潜在的病因。如果没有确定病因,这种情况被称为特发性泪腺炎。本报告的目的是提出一例特发性硬化性泪腺炎,并回顾其诊断过程。我们报告了一例对全身抗生素和类固醇无反应的硬化性泪腺炎,在手术拆封/活检后有所改善。全身炎症和感染实验室均为阴性。组织对严重急性呼吸系统综合征冠状病毒2型抗原呈阴性。手术标本的组织病理学检查显示非特异性硬化性泪腺炎,最终支持特发性非特异性纤维化泪腺炎的诊断。本病例回顾了常见眼眶病理状况的表现、评估和管理,并根据最新文献提出了最新建议。
{"title":"Idiopathic sclerosing dacryoadenitis.","authors":"Samantha D Butterfield, Rona Z Silkiss","doi":"10.1186/s12348-023-00365-y","DOIUrl":"10.1186/s12348-023-00365-y","url":null,"abstract":"<p><p>Dacryoadenitis is an inflammation of the lacrimal gland. This condition has an extensive differential diagnosis, requiring a thorough workup to identify the underlying etiology. If no etiology is identified, the condition is termed idiopathic dacryoadenitis. The purpose of this report is to present a case of idiopathic sclerosing dacryoadenitis and review the diagnostic process.We present a case of sclerosing dacryoadenitis non responsive to systemic antibiotics and steroids, improving after surgical debulking/biopsy. Systemic inflammatory and infectious labs were negative. Tissue was negative for SARS-CoV-2 antigen. Histopathologic review of the surgical specimen revealed nonspecific, sclerosing dacryoadenitis, ultimately supporting the diagnosis of idiopathic nonspecific fibrosing dacryoadenitis.This case reviews the presentation, evaluation, and management of a common orbital pathologic condition, with updated recommendations based on the most current literature.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"13 1","pages":"43"},"PeriodicalIF":2.9,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10657385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ocular sarcoidosis in adults and children: update on clinical manifestation and diagnosis. 成人和儿童眼部结节病:临床表现和诊断的最新进展。
IF 2.9 Q2 Medicine Pub Date : 2023-09-18 DOI: 10.1186/s12348-023-00364-z
Magdalena Bazewicz, Jarmila Heissigerova, Carlos Pavesio, François Willermain, Janusz Skrzypecki

Sarcoidosis-associated uveitis, is the predominant ocular sarcoidosis presentation, which affects both adults and children. For adults, international ocular sarcoidosis criteria (IWOS) and sarcoidosis-associated uveitis criteria (SUN) are defined. However, for children they are not yet established internationally. Due to the specificity of pediatric manifestations of sarcoidosis, this task is even more challenging. In children, sarcoidosis is subdivided into Blau syndrome and early-onset sarcoidosis (BS/EOS) affecting younger children (< 5 years) and the one affecting older children with clinical presentation resembling adults. Differential diagnosis, clinical work-up as well as diagnostic criteria should be adapted to each age group. In this article, we review the clinical manifestation of sarcoidosis-associated uveitis in adults and children and the sensitivity and specificity of various ocular sarcoidosis diagnostic modalities, including chest X-ray and CT, FDG PET-CT, gallium-67 scintigraphy, bronchoalveolar lavage fluid, genetic testing for NOD2 mutations and serum biomarkers, such as ACE, lysozyme and IL2R.

结节病相关葡萄膜炎是主要的眼部结节病表现,影响成人和儿童。对于成人,定义了国际眼部结节病标准(IWOS)和结节病相关葡萄膜炎标准(SUN)。然而,对于儿童来说,它们还没有在国际上建立起来。由于结节病儿童表现的特殊性,这项任务更具挑战性。在儿童中,结节病可细分为Blau综合征和影响幼儿的早发性结节病(BS/EOS)(
{"title":"Ocular sarcoidosis in adults and children: update on clinical manifestation and diagnosis.","authors":"Magdalena Bazewicz, Jarmila Heissigerova, Carlos Pavesio, François Willermain, Janusz Skrzypecki","doi":"10.1186/s12348-023-00364-z","DOIUrl":"10.1186/s12348-023-00364-z","url":null,"abstract":"<p><p>Sarcoidosis-associated uveitis, is the predominant ocular sarcoidosis presentation, which affects both adults and children. For adults, international ocular sarcoidosis criteria (IWOS) and sarcoidosis-associated uveitis criteria (SUN) are defined. However, for children they are not yet established internationally. Due to the specificity of pediatric manifestations of sarcoidosis, this task is even more challenging. In children, sarcoidosis is subdivided into Blau syndrome and early-onset sarcoidosis (BS/EOS) affecting younger children (< 5 years) and the one affecting older children with clinical presentation resembling adults. Differential diagnosis, clinical work-up as well as diagnostic criteria should be adapted to each age group. In this article, we review the clinical manifestation of sarcoidosis-associated uveitis in adults and children and the sensitivity and specificity of various ocular sarcoidosis diagnostic modalities, including chest X-ray and CT, FDG PET-CT, gallium-67 scintigraphy, bronchoalveolar lavage fluid, genetic testing for NOD2 mutations and serum biomarkers, such as ACE, lysozyme and IL2R.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"13 1","pages":"41"},"PeriodicalIF":2.9,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10636203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of intravitreal dexamethasone implant used as monotherapy for the treatment of macular edema in non-infectious uveitis: a retrospective analysis. 玻璃体内地塞米松植入物作为单一疗法治疗非感染性葡萄膜炎黄斑水肿的疗效:回顾性分析。
IF 2.9 Q2 Medicine Pub Date : 2023-09-18 DOI: 10.1186/s12348-023-00360-3
Rishi B Gupta, Julius Ilin, Chloe C Gottlieb

Background: Uveitic macular edema is a complication of acute or chronic uveitis. Current treatment regiments frequently have numerous side effects, often requiring supplemental treatment. This study investigates the efficacy of dexamethasone (DEX) intravitreal implants as monotherapy for treatment of macular edema in non-infectious intermediate, posterior or panuveitis.

Methods and results: Retrospective chart review of thirty patients with intermediate, posterior and panuveitis treated with DEX. Outcomes measured were central retinal thickness (CRT) and best corrected visual acuity (BCVA). Baseline measurements of CRT and BCVA were measured within 1 month prior to intravitreal DEX implant and follow up measurements were collected until 1 year post implant. 48 implants on 39 eyes of 30 patients were included in this study; 64.1% of patients had an improvement in BCVA and 65.4% had a reduction in CRT. BCVA improved from 0.285 logMAR (SD: 0.312) at baseline to 0.175 logMAR (SD: 0.194) at 1 month and was sustained thereafter. Preliminary CRT data showed a decrease from 392 [Formula: see text] (SD: [Formula: see text]) at baseline to 303 [Formula: see text] (SD: [Formula: see text] at 1 month and 313 [Formula: see text] (SD: [Formula: see text] at 12 months.

Conclusions: The DEX implant as monotherapy for macular edema in non-infectious uveitis was associated with a reduction in CRT and improvement in BCVA. The DEX implant, used as a monotherapy in eyes with intermediate, posterior and panuveitis, has the potential to treat uveitis without oral corticosteroid or other immunomodulatory therapy.

背景:葡萄膜炎性黄斑水肿是急性或慢性葡萄膜炎的并发症。目前的治疗方案经常有许多副作用,通常需要补充治疗。本研究探讨地塞米松(DEX)玻璃体内植入物作为单一疗法治疗非感染性中、后或全葡萄膜炎黄斑水肿的疗效。方法和结果:回顾性分析30例DEX治疗的中、后葡萄膜炎和全葡萄膜炎患者。测量的结果是视网膜中央厚度(CRT)和最佳矫正视力(BCVA)。在玻璃体内DEX植入前1个月内测量CRT和BCVA的基线测量值,并收集随访测量值,直到植入后1年。本研究包括30例患者39眼的48个植入物;64.1%的患者BCVA改善,65.4%的患者CRT降低。BCVA从基线时的0.285 logMAR(SD:0.312)改善到1个月时的0.175 logMAR(SD:0.194),并在此后持续。初步CRT数据显示,从基线时的392[公式:见正文](SD:[公式:见图正文])降至1个月时的303[公式:参见正文](SD:[公式:详见正文]12个月时。结论:DEX植入物作为非感染性葡萄膜炎黄斑水肿的单一疗法与CRT的减少和BCVA的改善有关。DEX植入物作为中间、后部和全葡萄膜炎眼的单一疗法,有可能在不使用口服皮质类固醇或其他免疫调节疗法的情况下治疗葡萄膜炎。
{"title":"Efficacy of intravitreal dexamethasone implant used as monotherapy for the treatment of macular edema in non-infectious uveitis: a retrospective analysis.","authors":"Rishi B Gupta, Julius Ilin, Chloe C Gottlieb","doi":"10.1186/s12348-023-00360-3","DOIUrl":"10.1186/s12348-023-00360-3","url":null,"abstract":"<p><strong>Background: </strong>Uveitic macular edema is a complication of acute or chronic uveitis. Current treatment regiments frequently have numerous side effects, often requiring supplemental treatment. This study investigates the efficacy of dexamethasone (DEX) intravitreal implants as monotherapy for treatment of macular edema in non-infectious intermediate, posterior or panuveitis.</p><p><strong>Methods and results: </strong>Retrospective chart review of thirty patients with intermediate, posterior and panuveitis treated with DEX. Outcomes measured were central retinal thickness (CRT) and best corrected visual acuity (BCVA). Baseline measurements of CRT and BCVA were measured within 1 month prior to intravitreal DEX implant and follow up measurements were collected until 1 year post implant. 48 implants on 39 eyes of 30 patients were included in this study; 64.1% of patients had an improvement in BCVA and 65.4% had a reduction in CRT. BCVA improved from 0.285 logMAR (SD: 0.312) at baseline to 0.175 logMAR (SD: 0.194) at 1 month and was sustained thereafter. Preliminary CRT data showed a decrease from 392 [Formula: see text] (SD: [Formula: see text]) at baseline to 303 [Formula: see text] (SD: [Formula: see text] at 1 month and 313 [Formula: see text] (SD: [Formula: see text] at 12 months.</p><p><strong>Conclusions: </strong>The DEX implant as monotherapy for macular edema in non-infectious uveitis was associated with a reduction in CRT and improvement in BCVA. The DEX implant, used as a monotherapy in eyes with intermediate, posterior and panuveitis, has the potential to treat uveitis without oral corticosteroid or other immunomodulatory therapy.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"13 1","pages":"42"},"PeriodicalIF":2.9,"publicationDate":"2023-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10506974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10653464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful treatment of multidrug-resistant Pseudomonas aeruginosa keratitis with meropenem eye drops - a case report. 美罗培南滴眼液成功治疗耐多药铜绿假单胞菌角膜炎1例报告。
IF 2.9 Q2 Medicine Pub Date : 2023-09-16 DOI: 10.1186/s12348-023-00363-0
Carolin Elhardt, Armin Wolf, Christian Maximilian Wertheimer

Background: This case report describes the course and therapeutic management of a fast-spreading bacterial keratitis caused by multidrug-resistant (MDR) Pseudomonas aeruginosa (P. aeruginosa).

Case presentation: A 27-year-old male contact lens wearer presented with a multi-resistant, fast spreading P. aeruginosa keratitis. After initial resistance to various antibiotic therapies, testing revealed a MDR P. aeruginosa. The keratitis was treated successfully with specially prepared 50 mg/ml off-label meropenem eye drops for 18 days as well as systemic meropenem for seven days with rapid improvement of the corneal infiltrate.

Conclusion: This case report demonstrates the combination of topical and systemic meropenem as a useful treatment option for corneal ulcers caused by MDR P. aeruginosa.

背景:本病例报告描述了由多重耐药(MDR)铜绿假单胞菌(P. aeruginosa)引起的快速传播的细菌性角膜炎的病程和治疗管理。病例介绍:一名27岁男性隐形眼镜佩戴者患有多重耐药、快速传播的铜绿假单胞菌性角膜炎。在最初对各种抗生素治疗产生耐药性后,检测发现了耐多药铜绿假单胞菌。经特殊配制的超说明书美罗培南滴眼液50 mg/ml治疗18天,并用全身美罗培南治疗7天,角膜浸润迅速改善。结论:本病例报告表明,局部和全身联合使用美罗培南是耐多药铜绿假单胞菌引起的角膜溃疡的有效治疗选择。
{"title":"Successful treatment of multidrug-resistant Pseudomonas aeruginosa keratitis with meropenem eye drops - a case report.","authors":"Carolin Elhardt, Armin Wolf, Christian Maximilian Wertheimer","doi":"10.1186/s12348-023-00363-0","DOIUrl":"10.1186/s12348-023-00363-0","url":null,"abstract":"<p><strong>Background: </strong>This case report describes the course and therapeutic management of a fast-spreading bacterial keratitis caused by multidrug-resistant (MDR) Pseudomonas aeruginosa (P. aeruginosa).</p><p><strong>Case presentation: </strong>A 27-year-old male contact lens wearer presented with a multi-resistant, fast spreading P. aeruginosa keratitis. After initial resistance to various antibiotic therapies, testing revealed a MDR P. aeruginosa. The keratitis was treated successfully with specially prepared 50 mg/ml off-label meropenem eye drops for 18 days as well as systemic meropenem for seven days with rapid improvement of the corneal infiltrate.</p><p><strong>Conclusion: </strong>This case report demonstrates the combination of topical and systemic meropenem as a useful treatment option for corneal ulcers caused by MDR P. aeruginosa.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"13 1","pages":"40"},"PeriodicalIF":2.9,"publicationDate":"2023-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10654434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recurrent superior orbital fissure syndrome associated with VEXAS syndrome. 复发性眶上裂综合征与VEXAS综合征相关。
IF 2.9 Q2 Medicine Pub Date : 2023-09-07 DOI: 10.1186/s12348-023-00362-1
Katie Myint, Namritha Patrao, Oana Vonica, Kaveh Vahdani

Purpose: To describe a case of recurrent orbital inflammation and superior orbital fissure syndrome associated with VEXAS (vacuoles, E1 enzyme, X-linked, auto-inflammatory, somatic) syndrome.

Case presentation: VEXAS syndrome is a recently identified multi-system inflammatory disease of late adult onset. The authors describe the case of a 76-year-old man who presented with recurrent episodes of orbital inflammation, with superior orbital fissure syndrome, dacryoadenitis and orbital myositis. He had a constellation of systemic disorders including recurrent chest infections, congestive cardiac failure, pulmonary emboli and skin rashes. The underlying diagnosis of VEXAS syndrome was confirmed by genetic testing, which revealed the UBA1 mutation.

Conclusion: VEXAS syndrome should be considered in the differential diagnosis of orbital inflammatory disease associated with multi-system inflammatory disorders.

目的:报道一例复发性眶炎和眶上裂综合征合并VEXAS(空泡,E1酶,x连锁,自身炎症,躯体)综合征的病例。病例介绍:VEXAS综合征是最近发现的一种多系统炎症性疾病,发病晚于成人。作者描述了一个76岁的男子谁提出了反复发作的眶炎,眶上裂综合征,泪腺炎和眶肌炎。他有一系列全身性疾病,包括复发性胸部感染、充血性心力衰竭、肺栓塞和皮疹。通过基因检测证实了VEXAS综合征的潜在诊断,发现了UBA1突变。结论:眼眶炎性疾病合并多系统炎性疾病的鉴别诊断应考虑VEXAS综合征。
{"title":"Recurrent superior orbital fissure syndrome associated with VEXAS syndrome.","authors":"Katie Myint, Namritha Patrao, Oana Vonica, Kaveh Vahdani","doi":"10.1186/s12348-023-00362-1","DOIUrl":"10.1186/s12348-023-00362-1","url":null,"abstract":"<p><strong>Purpose: </strong>To describe a case of recurrent orbital inflammation and superior orbital fissure syndrome associated with VEXAS (vacuoles, E1 enzyme, X-linked, auto-inflammatory, somatic) syndrome.</p><p><strong>Case presentation: </strong>VEXAS syndrome is a recently identified multi-system inflammatory disease of late adult onset. The authors describe the case of a 76-year-old man who presented with recurrent episodes of orbital inflammation, with superior orbital fissure syndrome, dacryoadenitis and orbital myositis. He had a constellation of systemic disorders including recurrent chest infections, congestive cardiac failure, pulmonary emboli and skin rashes. The underlying diagnosis of VEXAS syndrome was confirmed by genetic testing, which revealed the UBA1 mutation.</p><p><strong>Conclusion: </strong>VEXAS syndrome should be considered in the differential diagnosis of orbital inflammatory disease associated with multi-system inflammatory disorders.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"13 1","pages":"39"},"PeriodicalIF":2.9,"publicationDate":"2023-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10186003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characterization of patients with HLA-B27-associated uveitis and evaluation of the impact of systemic treatment on the recurrence rate: a cross-sectional study. hla - b27相关性葡萄膜炎患者的临床特征和评估全身治疗对复发率的影响:一项横断面研究
IF 2.9 Q2 Medicine Pub Date : 2023-08-30 DOI: 10.1186/s12348-023-00352-3
Juan Sebastián Pineda-Sierra, Carlos Cifuentes-González, William Rojas-Carabali, Paula Tatiana Muñoz-Vargas, Alejandro Henao-Posada, Alejandra de-la-Torre

Introduction: Despite HLA-B27-associated uveitis is one of the most frequent etiologies of uveitis worldwide, there are scarce studies on the clinical spectrum of this disease and the implications of therapeutic strategies used in the Latin-American population, with none conducted in Colombia. Thus, this study aimed to describe the clinical characteristics of a cohort of patients with positive HLA-B27-associated uveitis in Colombia and evaluate the impact of systemic treatment on the recurrence rate.

Methods: We retrospectively reviewed 490 clinical charts of patients with uveitis, searching for those with positive HLA-B27-associated uveitis over eight years in a referral center in Bogotá, Colombia. We used descriptive statistics to summarize demographic and clinical characteristics and conducted a Chi-square test, Fisher Exact test, Spearman correlation, and Mann-Whitney test to assess associations between treatment strategies and the recurrences rate.

Results: We analyzed 39 patients (59% females) with positive HLA-B27-associated uveitis, with a median age at the first consultation of 44.5 years (Range: 2-80) and a mean follow-up time of 86.4 weeks (1.65 years). Most patients had unilateral uveitis (53.8%) and an anterior anatomical diagnosis (76.6%); two had anterior chamber fibrinous reaction, and only one had hypopyon. Most patients did not show associated systemic symptoms (66.7%). Topical corticosteroids, NSAIDs, methotrexate, mydriatics, and adalimumab were the most used treatments. The most common complications included cataracts, posterior synechiae, and macular edema. We identified that the rate of recurrences decreases over time (r = -0.6361, P = 0.002571), and this decrease seems to be associated with the initiation of disease-modifying antirheumatic drugs (DMARDs) in chronic and recurrent cases.

Conclusion: The clinical spectrum of HLA-B27-associated uveitis in Colombian patients is distinct from other latitudes. Notably, we found a female predominance, older age at presentation, higher frequency of bilateral and vitreous involvement, and lower frequency of concomitant systemic diseases. Additionally, our results suggest that DMARDs such as methotrexate and biologic agents are good therapeutic options to avoid recurrences in chronic and recurrent cases.

导语:尽管hla - b27相关的葡萄膜炎是世界范围内葡萄膜炎最常见的病因之一,但关于这种疾病的临床谱和拉丁美洲人群中使用的治疗策略的影响的研究很少,在哥伦比亚没有进行过研究。因此,本研究旨在描述哥伦比亚一组hla - b27阳性相关性葡萄膜炎患者的临床特征,并评估全身治疗对复发率的影响。方法:我们回顾性地回顾了490例葡萄膜炎患者的临床图表,在哥伦比亚波哥大的一家转诊中心寻找8年来hla - b27相关葡萄膜炎阳性患者。我们使用描述性统计来总结人口学和临床特征,并进行卡方检验、Fisher精确检验、Spearman相关检验和Mann-Whitney检验来评估治疗策略与复发率之间的关系。结果:我们分析了39例hla - b27相关葡萄膜炎阳性患者(59%为女性),首次就诊时的中位年龄为44.5岁(范围:2-80岁),平均随访时间为86.4周(1.65年)。大多数患者为单侧葡萄膜炎(53.8%),前解剖诊断(76.6%);2例有前房纤维性反应,1例有垂体后叶。大多数患者未出现相关的全身症状(66.7%)。外用皮质类固醇、非甾体抗炎药、甲氨蝶呤、mydritics和阿达木单抗是最常用的治疗方法。最常见的并发症包括白内障、后粘连和黄斑水肿。我们发现复发率随着时间的推移而降低(r = -0.6361, P = 0.002571),这种降低似乎与慢性和复发病例开始使用改善疾病的抗风湿药物(DMARDs)有关。结论:哥伦比亚患者hla - b27相关性葡萄膜炎的临床谱不同于其他纬度地区。值得注意的是,我们发现女性居多,发病年龄较大,双侧和玻璃体受累的频率较高,而伴随全身性疾病的频率较低。此外,我们的研究结果表明,DMARDs如甲氨蝶呤和生物制剂是避免慢性和复发病例复发的良好治疗选择。
{"title":"Clinical characterization of patients with HLA-B27-associated uveitis and evaluation of the impact of systemic treatment on the recurrence rate: a cross-sectional study.","authors":"Juan Sebastián Pineda-Sierra, Carlos Cifuentes-González, William Rojas-Carabali, Paula Tatiana Muñoz-Vargas, Alejandro Henao-Posada, Alejandra de-la-Torre","doi":"10.1186/s12348-023-00352-3","DOIUrl":"10.1186/s12348-023-00352-3","url":null,"abstract":"<p><strong>Introduction: </strong>Despite HLA-B27-associated uveitis is one of the most frequent etiologies of uveitis worldwide, there are scarce studies on the clinical spectrum of this disease and the implications of therapeutic strategies used in the Latin-American population, with none conducted in Colombia. Thus, this study aimed to describe the clinical characteristics of a cohort of patients with positive HLA-B27-associated uveitis in Colombia and evaluate the impact of systemic treatment on the recurrence rate.</p><p><strong>Methods: </strong>We retrospectively reviewed 490 clinical charts of patients with uveitis, searching for those with positive HLA-B27-associated uveitis over eight years in a referral center in Bogotá, Colombia. We used descriptive statistics to summarize demographic and clinical characteristics and conducted a Chi-square test, Fisher Exact test, Spearman correlation, and Mann-Whitney test to assess associations between treatment strategies and the recurrences rate.</p><p><strong>Results: </strong>We analyzed 39 patients (59% females) with positive HLA-B27-associated uveitis, with a median age at the first consultation of 44.5 years (Range: 2-80) and a mean follow-up time of 86.4 weeks (1.65 years). Most patients had unilateral uveitis (53.8%) and an anterior anatomical diagnosis (76.6%); two had anterior chamber fibrinous reaction, and only one had hypopyon. Most patients did not show associated systemic symptoms (66.7%). Topical corticosteroids, NSAIDs, methotrexate, mydriatics, and adalimumab were the most used treatments. The most common complications included cataracts, posterior synechiae, and macular edema. We identified that the rate of recurrences decreases over time (r = -0.6361, P = 0.002571), and this decrease seems to be associated with the initiation of disease-modifying antirheumatic drugs (DMARDs) in chronic and recurrent cases.</p><p><strong>Conclusion: </strong>The clinical spectrum of HLA-B27-associated uveitis in Colombian patients is distinct from other latitudes. Notably, we found a female predominance, older age at presentation, higher frequency of bilateral and vitreous involvement, and lower frequency of concomitant systemic diseases. Additionally, our results suggest that DMARDs such as methotrexate and biologic agents are good therapeutic options to avoid recurrences in chronic and recurrent cases.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"13 1","pages":"38"},"PeriodicalIF":2.9,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10134141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting macrophage migration inhibitory factor (MIF): a promising therapy for inflammatory ocular diseases. 靶向巨噬细胞迁移抑制因子(MIF):一种治疗炎性眼病的新方法。
IF 2.9 Q2 Medicine Pub Date : 2023-08-25 DOI: 10.1186/s12348-023-00361-2
Alicia Vázquez, Marisol I González, José L Reyes

Inflammatory ocular diseases are characterized by the presence of a persistent inflammatory response which cause tissue injury, decrease visual acuity and in severe cases, blindness. Several cytokines represent a therapeutic opportunity since they are key amplifiers of these pathologies, and thus neutralizing agents against them have been developed. Amongst others, macrophage migration inhibitory factor (MIF), an early produced inflammatory cytokine, has consistently been found elevated in patients with distinct ocular diseases (inflammatory and autoimmune). Here, we present and discuss evidence showing that preclinical trials using diverse strategies to neutralize MIF resulted in significant attenuation of disease signs and therefore MIF blockage might be a promising therapy for ocular diseases.

炎症性眼部疾病的特点是存在持续的炎症反应,导致组织损伤,视力下降,严重时导致失明。一些细胞因子代表了治疗的机会,因为它们是这些病理的关键放大器,因此针对它们的中和剂已经开发出来。其中,巨噬细胞迁移抑制因子(MIF)是一种早期产生的炎症细胞因子,在患有不同眼部疾病(炎症性和自身免疫性)的患者中一直被发现升高。在这里,我们提出并讨论了证据,表明临床前试验使用不同的策略来中和MIF导致疾病症状的显著衰减,因此MIF阻断可能是一种有希望的眼部疾病治疗方法。
{"title":"Targeting macrophage migration inhibitory factor (MIF): a promising therapy for inflammatory ocular diseases.","authors":"Alicia Vázquez, Marisol I González, José L Reyes","doi":"10.1186/s12348-023-00361-2","DOIUrl":"10.1186/s12348-023-00361-2","url":null,"abstract":"<p><p>Inflammatory ocular diseases are characterized by the presence of a persistent inflammatory response which cause tissue injury, decrease visual acuity and in severe cases, blindness. Several cytokines represent a therapeutic opportunity since they are key amplifiers of these pathologies, and thus neutralizing agents against them have been developed. Amongst others, macrophage migration inhibitory factor (MIF), an early produced inflammatory cytokine, has consistently been found elevated in patients with distinct ocular diseases (inflammatory and autoimmune). Here, we present and discuss evidence showing that preclinical trials using diverse strategies to neutralize MIF resulted in significant attenuation of disease signs and therefore MIF blockage might be a promising therapy for ocular diseases.</p>","PeriodicalId":16600,"journal":{"name":"Journal of Ophthalmic Inflammation and Infection","volume":"13 1","pages":"37"},"PeriodicalIF":2.9,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10078516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Ophthalmic Inflammation and Infection
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1